
    
      This is a multicenter single-arm clinical study including male and female subjects with
      moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or
      chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will
      be enrolled in 10 study sites in France.

      The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks.

      The objectives of the study are to assess the efficacy of intravesical instillations of
      INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is
      the evaluation of pain using a verbal rating scale one week and four weeks after treatment
      versus Baseline.
    
  